Soluble tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (sTRAIL-R1) also known as DR4, is encoded by the gene mapped to human chromosome 8p21-22. Recombinant human soluble TRAIL Receptor-1/DR4 is a 22.7kDa protein (216 amino acid residues) consisting of the TNFR homologous, cysteine rich portion of the extracellular domain. TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins. TRAIL-R1 contains a cytoplasmic "death domain," which can activate the cell′s apoptotic machinery. TRAIL Receptor-1/DR4 is activated by binding to either membrane anchored or soluble TRAIL/Apo2L.
Soluble tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (sTRAIL-R1) interacts with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and stimulate cell-death signaling pathway. Mutation of the sTRAIL-R1 gene is associated with the pathogenesis of non-Hodgkinμs lymphoma (NHL). In addition, variation of TRAIL-R1 also increases the risk of susceptibility to prostate cancer (PCa) in North Indian population.
